[Ad hoc announcement pursuant to Art. 53 LR] Roche reports good sales growth in the first quarter of 2022

Basel, 25 April 2022Group sales increase 11%1 at constant exchange rates (CER) and 10% in Swiss francsPharmaceuticals Divisionsales up 6%; continued strong sales of new medicines for severe diseases. Impact of biosimilars decreases as expected.Diagnostics Divisionsales grow 24% due to good momentum in base business and continued high demand for COVID-19 tests. After a strong first quarter, significant decline in COVID-19-related testing expected.Highlights in the first quarter:FDA approval of Vabysmo (severe eye diseases); CHMP recommends EU approval of Polivy combination (aggressive form of blood cancer), Tecentriq (early-stage non-small cell lung cancer) and mosunetuzumab (follicular lymphoma)Positive long-term data for Evrysdi (spinal muscular atrophy) and for Vabysmo and Susvimo (severe eye diseases)Roche provides molecular testing solutions to identify and differentiate SARS-CoV-2 Omicron variantsOutlook for 2022 confirmedCommenting on the Group ’s sales, Roche CEO Severin Schwan said: “As expected, we started the year with strong demand for our diagnostics base business, our broad portfolio of COVID-19 tests and our new medicines. I am particularly pleased about the progress we are making in developing our product pipeline, including p ositive new data in neurology as well as in severe eye diseases. Based on our current assessment of the development of the COVID-19 pandemic, we confirm the outlook for the full year.”SalesCHF millionsAs % of sales% changeJanuary - ...
Source: Roche Media News - Category: Pharmaceuticals Source Type: news
More News: Academies | Actemra | Activase | Acute Leukemia | African Health | Age-Related Macular Degeneration (AMD) | Allergy & Immunology | Alzheimer's | Appendicitis | Arthritis | Asthma | Autoimmune Disease | Avastin | Biotechnology | Bladder Cancer | Boys | Brain | Brain Cancers | Brain Tumor | Breast Cancer | Canada Health | Cancer | Cancer & Oncology | Cancer Vaccines | Cervical Cancer | Chemistry | Chemotherapy | Child Development | Children | China Health | Chronic Leukemia | Chronic Lymphocytic Leukemia | Clinical Trials | Colorectal Cancer | Conferences | Covid Vaccine | COVID-19 | Diabetes | Diabetes Type 2 | Disability | Economic Slowdown | Emergency Medicine | Endocrinology | European Medicines Agency (EMA) | Eyes | Gastric (Stomach) Cancer | Gastroenterology | Gene Therapy | Genetics | Germany Health | Government | Graduation | Haemophilia | Heart Attack | Hemophilia | HER2 | Herceptin | History of Medicine | Hives | Hodgkin's Disease | Hospitals | Immunotherapy | India Health | Information Technology | International Medicine & Public Health | Italy Health | Japan Health | Kidney Transplant | Leukemia | Liver | Liver Transplant | Lucentis | Lung Cancer | Lung Transplant | Lymphoma | Marketing | Men | Middle East Health | Multiple Sclerosis | Muscular Dystrophy | Neoadjuvant Chemotherapy Therapy | Neoadjuvant Therapy | Neurology | Neuroscience | Non-Hodgkin's Lymphoma | Non-Small Cell Lung Cancer | Ovarian Cancer | Ovaries | Pandemics | Pathology | Pharmaceuticals | Pneomococcal Vaccine | Pneumonia | Primary CNS Lymphoma | Profits and Losses | Pulmozyme | Ranibizumab Injection | Rare Diseases | Reflex Sympathetic Dystrophy | Rheumatoid Arthritis | Rheumatology | Rituxan | Russia Health | SARS | Science | Small Cell Lung Cancer | Spinal Muscular Atrophy | Study | Switzerland Health | Turkey Health | Urology & Nephrology | USA Health | Vaccines | Vasculitis | Virology | Xolair